<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019768</url>
  </required_header>
  <id_info>
    <org_study_id>127</org_study_id>
    <nct_id>NCT05019768</nct_id>
  </id_info>
  <brief_title>Topo-pachimetric Accelerated Epi-On Cross-linking Compared to Dresden Protocol Using Riboflavin With Vitamin E TPGS</brief_title>
  <official_title>Topo-pachimetric Accelerated Epi-On Cross-linking Compared to Dresden Protocol Using Riboflavin With Vitamin E TPGS: Results of a 2-year Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciro Caruso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corneal Transplant Center, Pellegrini Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study the investigators compare the clinical outcome corneal cross linking&#xD;
      with either the stand-ard Dresden (sCXL) or the accelerated custom-fast (aCFXL) ultraviolet A&#xD;
      irradiation protocol using riboflavin-D-α-Tocopheryl polyethyleneglycol1000 succinate for&#xD;
      progressive keratoconus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Topographical parameters</measure>
    <time_frame>2 years</time_frame>
    <description>Maximum keratometry: diopters Mean keratometry: diopters Minimum corneal tickness: diopters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Refractive parameters</measure>
    <time_frame>2 years</time_frame>
    <description>Corrected distance acuity (BCVA): Logarithm of the Minimum Angle of Resolution (logMAR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refractive parameters</measure>
    <time_frame>2 years</time_frame>
    <description>Spherical equi-valent: diopters Refractive cylinder magnitude: diopters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomechanical parameters</measure>
    <time_frame>2 years</time_frame>
    <description>Corneal hysteresis: mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>sCXL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard protocol of Dresden Riboflavin-VEPTGS solution applied every 2 mins during UV UVA fluence of 3mW/cm2 UVA Irradiation time 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aCFXL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Accelerated custom fast CXL protocol. The protocol has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin con-sumption rate and the corneal thickness at its thinnest point.&#xD;
Riboflavin-VEPTGS solution: Epithelial lavage before UV UVA fluence of 1.8 ±0.9 mW/cm2 UVA Irradiation time 10 ± 1.5 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>accelerated custom-fast CXL</intervention_name>
    <description>The accelerated custom fast CXL (aCFXL) has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin consumption rate and the corneal thickness at its thinnest point. By knowing both values, the mathematical model allows to objectively calculate both the exact UVA irradiation value (intensity), expressed in mW/cm2, and the irradiation time</description>
    <arm_group_label>aCFXL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard CXL</intervention_name>
    <description>The standard CXL procedure has been carried on following the Dresden protocol</description>
    <arm_group_label>sCXL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  documented progressive keratoconus&#xD;
&#xD;
          -  changes in uncorrected distance visual acuity (UDVA) above 1.00 D&#xD;
&#xD;
          -  Corrected distance visual acuity (BCVA) above 1.00 D&#xD;
&#xD;
          -  spherical equivalent greater than 0.50 D&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Corneal pachymetry of less than 400 µm&#xD;
&#xD;
          -  less than 2000 cells/cm2,&#xD;
&#xD;
          -  corneal scarring,&#xD;
&#xD;
          -  nystagmus or any motility disorder that prevented a fixed gaze during the examination&#xD;
&#xD;
          -  Current contact lens use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pellegrini Hospital</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Caruso C, Ostacolo C, Epstein RL, Barbaro G, Troisi S, Capobianco D. Transepithelial Corneal Cross-Linking With Vitamin E-Enhanced Riboflavin Solution and Abbreviated, Low-Dose UV-A: 24-Month Clinical Outcomes. Cornea. 2016 Feb;35(2):145-50. doi: 10.1097/ICO.0000000000000699.</citation>
    <PMID>26606293</PMID>
  </reference>
  <reference>
    <citation>Caruso C, Epstein RL, Ostacolo C, Pacente L, Troisi S, Barbaro G. Customized Corneal Cross-Linking-A Mathematical Model. Cornea. 2017 May;36(5):600-604. doi: 10.1097/ICO.0000000000001160.</citation>
    <PMID>28257382</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Corneal Transplant Center, Pellegrini Hospital</investigator_affiliation>
    <investigator_full_name>Ciro Caruso</investigator_full_name>
    <investigator_title>MD, Head of Corneal Transplant Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

